These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 25867204)
21. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility. Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942 [TBL] [Abstract][Full Text] [Related]
22. Hemolytic adverse effects of intravenous immunoglobulin: modeling predicts risk reduction with anti-A/B immunoaffinity chromatography and to a lesser extent with anti-A donor screening. Mallick R; Hubsch A; Barnes DG Transfusion; 2018 Dec; 58(12):2752-2756. PubMed ID: 30284263 [TBL] [Abstract][Full Text] [Related]
23. Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. Lally K; Kruse RL; Smetana H; Davis R; Roots A; Marshall C; Ness PM; DeZern AE; Gladstone DE; Brennan DC; Desai NM; Tobian AAR; Bloch EM; Gehrie EA Transfusion; 2020 Mar; 60(3):628-636. PubMed ID: 31957889 [TBL] [Abstract][Full Text] [Related]
24. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Padmore R Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898 [TBL] [Abstract][Full Text] [Related]
25. Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products. McVey J; Baker D; Parti R; Berg R; Gudino M; Teschner W Transfusion; 2015 Jul; 55 Suppl 2():S98-104. PubMed ID: 25981342 [TBL] [Abstract][Full Text] [Related]
27. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. Menis M; Sridhar G; Selvam N; Ovanesov MV; Divan HA; Liang Y; Scott D; Golding B; Forshee R; Ball R; Anderson SA; Izurieta HS Am J Hematol; 2013 Dec; 88(12):1035-40. PubMed ID: 23907744 [TBL] [Abstract][Full Text] [Related]
28. Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy. Mohamed M; Bates G; Eastley B Br J Haematol; 2013 Mar; 160(5):570. PubMed ID: 23294261 [No Abstract] [Full Text] [Related]
29. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192 [TBL] [Abstract][Full Text] [Related]
30. Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. Sinclair CJ; Brooks W; Genereux MG Biologicals; 2008 Jul; 36(4):256-62. PubMed ID: 18406165 [TBL] [Abstract][Full Text] [Related]